Yes, prescription coverage for Alzheimer's drugs stays protected while you stay enrolled in Medicaid. The 2025 cuts do not delete covered drug classes; they end eligibility for some adults.
KFF explains that Medicaid's outpatient drug rule creates a near-open formulary. States that cover outpatient drugs must cover nearly all FDA-approved drugs from makers with a federal rebate agreement. Staying enrolled keeps that rule working for you.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official notice from FDA — Use this primary source to verify the official announcement.
- Read the official guidance from FDA — Use this primary source to verify the official guidance.
Table of Contents
- What Medicaid must still cover
- Which Alzheimer's treatments are included
- Why some people still lose drug help
- What to do to protect access
What Medicaid must still cover
KFF describes the core protection in the KFF rebate explainer. States with outpatient drug coverage must cover nearly all FDA-approved drugs from participating makers. That protection continues for enrolled beneficiaries after the cuts. The same drug can still require extra steps.
The National Association of Medicaid Directors notes that states may use preferred drug lists, prior authorization, quantity limits, and nominal cost-sharing. A covered Alzheimer's prescription may need doctor paperwork, a specific pharmacy, or a renewal review. This matters for planning. Coverage means the drug class remains available, not that every prescription fills without review. Families should expect approval rules to continue alongside the formulary protection.
Which Alzheimer's treatments are included
The FDA converted Leqembi, lecanemab-irmb, to traditional approval on July 6, 2023, after a confirmatory trial verified clinical benefit. The agency announced the decision in the FDA approval announcement. The FDA also approved Kisunla, donanemab-azbt, for Alzheimer's treatment on July 2, 2024. These are amyloid-directed monoclonal antibodies.
That term means laboratory-made antibodies designed to attach to amyloid plaques in the brain. CMS applies a separate coverage policy, National Coverage Determination 200.3, that covers this group only with evidence development for mild cognitive impairment or mild dementia with confirmed amyloid pathology, including registry or study participation. For Medicaid enrollees, the rebate rule is the main prescription shield. For Medicare, the CMS evidence-development terms add eligibility and documentation limits. People with both programs should track both sets of rules.
Why some people still lose drug help
KFF finds the law works mainly by ending eligibility rather than removing drugs. Congress's 2025 reconciliation law, H.R. 1, cuts federal Medicaid spending by about $911 billion over 10 years. KFF, summarizing federal estimates, projects 10 million more uninsured people in 2034. The law requires states to condition Medicaid eligibility for ACA-expansion adults on work or community-engagement rules starting January 1, 2027.
KFF notes that earlier state implementation is permitted. Losing eligibility ends both the prescription benefit and help with premiums and cost-sharing. That loss hits older adults hard. KFF estimates about 1.3 million low-income Medicare beneficiaries will face higher costs, explained in the KFF analysis of cost effects. For a person with early Alzheimer's, losing Medicaid can mean losing help paying for visits, scans, infusions, and related prescriptions.
What to do to protect access
Check your eligibility group now, especially if you entered Medicaid through expansion. Watch every renewal letter, deadline, and work-reporting notice from your state.
A missed form can end coverage even when the drug benefit itself has not changed. Bring that packet to each neurology visit and pharmacy refill. If coverage lapses, ask the clinic social worker about reapplication, appeal deadlines, and temporary supply options the same week.
- Confirm your renewal date and required documents with the state Medicaid office
- Ask your clinic what prior authorization your Alzheimer's drug needs
- Keep amyloid test results, diagnosis stage, and specialist notes together
- If you have Medicare too, ask what cost-sharing help you receive
